What value do norepinephrine/dopamine dual reuptake inhibitors have to the current treatment of adult attention deficit hyperactivity disorder (ADHD) treatment armamentarium?

Click to increase image sizeClick to decrease image size

Declaration of interest

G Perugi acted as consultant to Lundbeck, Angelini, and Neuraxpharm. He received a scholarship/research support from Lundbeck and Angelini. He is a member of the speaker/advisory board of Sanofi-Aventis, Lundbeck, FB-Health, and Angelini. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have disclosed researcher, speaker and consultancy roles for various companies relevant to the field, including Shire, McNeal, Lilly, Supernus, Corium, Ironshore, GlaxoWelcome, Rhodes, Novartis. Peer reviewers on this manuscript have no other relevant financial relationships to disclose.

Additional information

Funding

This paper was not funded.